Teva recalls opioid dependence drug; U.S. API makers tell FDA they want regular inspections;

> India's Shasun Pharmaceuticals said it intends to grow its formulations manufacturing to 40% of its business to move up from being primarily an API maker. Story

> Teva ($TEVA) is recalling 70,633 bottles of sublingual tablets of its opioid dependence drug buprenorphine hydrochloride because of high levels of impurities. Notices here and here

> SigmaPharm Laboratories has recalled more than 43,000 bottles of liothyronine sodium tablets because of the possibility of cross contamination with other products. Notice

> Forest Laboratories ($FRX) has recalled nearly 22,000 bottles of blood pressure drug bystolic because samples failed dilutions testing. Notice

> EU regulators say that a focus this year will be on dealing with drug shortages caused by manufacturing problems. Story

> Almac has invested in new equipment at its Craigavon, UK headquarters to to meet new FDA mandates for testing for heavy metals. Release

> Upsher-Smith Laboratories has an agreement with Sandoz for potassium chloride manufacturing, supply and distribution. Release

And Finally... The Bulk Pharmaceuticals Task Force (BPTF) of the Society of Chemical Manufacturers and Affiliates (SOCMA) has told the FDA it is concerned about agency plans to cut back on inspections of domestic active pharmaceutical ingredient (API) manufacturers to focus on high-risk areas outside the U.S. Release

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.